cryptobiotech

LA PALMA, CALIFORNIA — In a groundbreaking development that bridges biotechnology and blockchain, Liminatus Pharma, Inc. (NASDAQ: LIMN) — a biotech firm specializing in preclinical cancer immunotherapies — has announced plans to invest up to $500 million in BNB Coin, marking a bold entry into the digital asset space.

🔬 Liminatus: From Biotech to Blockchain

With a market cap of $226.59 million, Liminatus Pharma is known for its innovative work in pancreatic cancer diagnostics and immunotherapy. Despite currently posting a negative EPS of -$0.14, the stock has soared over 56% in the past week, driven by its crypto expansion plan and capital restructuring efforts.

💼 Introducing “American BNB Strategy” Subsidiary

To execute its BNB investment, Liminatus has launched a new crypto-focused subsidiary named American BNB Strategy. The investment will be rolled out gradually, totaling $500 million.

CEO Chris Kim emphasized this is a long-term strategic value investment, not speculative trading. He pointed to the BNB ecosystem’s growth, including features like Launchpool, staking, and Binance’s global user base, as key drivers behind the move.

🔐 Secured by Ceffu: Institutional-Grade Custody

The investment will be securely managed through Ceffu, Binance’s institutional crypto custody platform. This ensures high-level asset security and operational transparency.

📈 Strengthening Capital Structure and Strategic Flexibility

Liminatus is not just diving into crypto. In partnership with Digital Offering LLC, it has initiated a capital raise using modern financial tools like convertible bonds and equity-linked securities.

It’s also exploring the integration of regulated digital assets into treasury management, showcasing a forward-thinking approach uncommon in the biotech space.

🤝 Leadership Reinforcement & Strategic Partnerships

To support its bold vision, Liminatus appointed Philip Lemons and Richard Baek to its Board of Directors, bringing seasoned leadership to the table.

Additionally, it executed a share-warrant exchange deal with Alta Partners, transferring 350,000 shares for 1 million warrants—with no commissions—signaling a long-term strategic alliance.

📊 Stock Performance: LIMN Surging Past Lows

Currently trading at $8.71, LIMN stock has nearly doubled from its 52-week low of $4.40. Increased volatility reflects strong market interest in the company’s diversification into crypto.

For more insights, investors can track real-time metrics on InvestingPro.

🧬 Conclusion: A Revolutionary Fusion of Biotech & Blockchain

Liminatus Pharma’s move into crypto signifies a bold new era where biotech firms can embrace blockchain to unlock financial agility and strategic growth. While continuing its core focus in immunotherapy, the company’s crypto strategy marks a pioneering model for industry evolution.

🚀 What’s Next?

Finalization of capital raise and regulatory clearances
Phased implementation of the BNB investment
Monitoring the impact of BNB price trends on LIMN valuation
Potential expansion into a broader digital asset portfolio

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

#BNBATH #CryptoBiotech #LIMNBNB #BinanceEcosystem @CZ @binance

Pacietība atmaksājas: Kāpēc $BIO ir vērts turēt

Ja jūs iegādājāties $BIO par augstāku cenu (ap $0.70 vai augstāk) un tagad skatāties, kā cena krīt, neļaujiet īstermiņa svārstībām satricināt jūsu pārliecību. Kriptovalūtu tirgus atlīdzina tos, kas tur $BIO projektus ar stabilām pamatvērtībām – un $BIO ir viens no tiem. Šeit ir iemesls, kāpēc palikt uz kursa varētu būt uzvarošā stratēģija.

Kāpēc $BIO ir pelnījusi vietu jūsu portfelī

1. Biotehnoloģiju jomas traucējumi

$BIO nav tikai vēl viena marķieris – tā ir biotehnoloģiju un decentralizētās zinātnes (DeSci) priekšgalā. Ar blokķēdes jaudotu pētījumu un inovāciju palīdzību, BIO protokols veido ceļu sasniegumiem medicīnā, ģenētikā un dzīvības zinātnēs.